Ionis Shares Jump as Q1 Revenue Surges 87% and Blockbuster Guidance Raised

Revenue and Earnings Outperform Expectations

Ionis Pharmaceuticals reported a robust first quarter for 2026, characterized by a massive 87% year-over-year increase in total revenue. The company brought in $246 million for the quarter, significantly exceeding the analyst consensus estimate of $195.6 million. This top-line strength was mirrored in the bottom line, where Ionis reported a GAAP EPS of -$0.48, beating the estimated loss of -$0.85 by a wide margin of $0.37. On a non-GAAP basis, the loss was even narrower at -$0.37 per share.

The revenue surge was driven by a combination of commercial product sales and substantial R&D milestones. The company earned $95 million in payments from clinical and regulatory milestones across its various partnerships. However, the real story for investors is the accelerating momentum of Ionis’ independent commercial portfolio, which is beginning to shift the company's financial profile from a pure R&D shop to a commercial powerhouse.

Commercial Momentum and Guidance Hike

In a move that caught the attention of Wall Street, Ionis management raised its annual peak net sales guidance for olezarsen in severe hypertriglyceridemia (sHTG) to over $3 billion, up from the previous forecast of over $2 billion. This 50% increase in peak guidance reflects growing confidence in the market opportunity for the drug, which is currently under Priority Review by the FDA with a PDUFA action date of June 30, 2026.

Existing commercial products also showed strong performance. TRYNGOLZA (olezarsen), recently approved for familial chylomicronemia syndrome (FCS), generated $27 million in U.S. net product sales. Meanwhile, DAWNZERA (donidalorsen) for hereditary angioedema saw its U.S. sales jump to $16 million, representing a 125% increase compared to the fourth quarter of 2025.

"Ionis’ strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines," said CEO Brett P. Monia, Ph.D. "Our independent launches are increasingly contributing to revenue, driven by strong commercial execution."

Pipeline Catalysts and Financial Position

The company is preparing for two additional major independent launches this year. Beyond the June target for olezarsen in sHTG, the FDA has accepted the New Drug Application for zilganersen for Alexander disease with a Priority Review date of September 22, 2026. If approved, zilganersen would be the first launch from Ionis' neurology pipeline.

From a balance sheet perspective, Ionis ended the quarter with $1.9 billion in cash and short-term investments. This remains a healthy cushion even after the company utilized $633 million to settle the maturity of its 0% convertible notes on April 1, 2026. CFO Elizabeth L. Hougen noted that the company's strong performance supports an improved 2026 financial guidance and keeps Ionis on track to reach its goal of cash-flow breakeven by 2028.

Market Reaction and Analyst Outlook

Following the release, IONS shares rose 3.39% to $74.68 in pre-market trading, up from a previous close of $72.23. Analysts are likely to view the DAWNZERA growth and the olezarsen guidance hike as evidence that Ionis is successfully navigating its transition to a self-sufficient commercial entity. The focus for the remainder of the year will shift to the upcoming FDA decisions and pivotal Phase 3 data readouts for partnered programs like bepirovirsen and pelacarsen.